On 19 September 2001, orphan designation (EU/3/01/058) was granted by the European Commission to Dompé s.p.a., Italy, for repertaxin l-lysinate salt for the prevention of delayed graft function in organ transplant.
The sponsorship was transferred to Dompé pha.r.ma s.p.a, Italy, in April 2007 and back to Dompé s.p.a., Italy, in February 2010. Finally, the sponsorship was transferred to Dompé farmaceutici s.p.a., Italy, in March 2015.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Repertaxin L-lysine salt
Prevention of delayed graft function in organ transplant
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: